<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03379506</url>
  </required_header>
  <id_info>
    <org_study_id>5172-079</org_study_id>
    <secondary_id>2015-003006-16</secondary_id>
    <secondary_id>MK-5172-079</secondary_id>
    <nct_id>NCT03379506</nct_id>
  </id_info>
  <brief_title>Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)</brief_title>
  <official_title>A Phase IIb Clinical Study to Assess the Pharmacokinetics, Safety, and Efficacy of the Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Participants Aged 3 to Less Than 18 Years With Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics (PK), safety, and efficacy of
      MK-5172, a fixed dose combination (FDC) of elbasvir (EBR) and grazoprevir (GZR) in pediatric
      hepatitis C virus (HCV)-infected participants aged 3 years up to 18 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Anticipated">April 9, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 9, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of EBR</measure>
    <time_frame>Week 4: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 24 hr</time_frame>
    <description>Area under the concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) of plasma EBR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of GZR</measure>
    <time_frame>Week 4: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 24 hr</time_frame>
    <description>Area under the concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) of plasma GZR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration of EBR</measure>
    <time_frame>Week 4: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 24 hr</time_frame>
    <description>Maximum observed concentration (Cmax) of plasma EBR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration of GZR</measure>
    <time_frame>Week 4: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 24 hr</time_frame>
    <description>Maximum observed concentration (Cmax) of plasma GZR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of EBR</measure>
    <time_frame>Week 4: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 24 hr</time_frame>
    <description>Apparent clearance (CL/F) of plasma EBR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of GZR</measure>
    <time_frame>Week 4: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 24 hr</time_frame>
    <description>Apparent clearance (CL/F) of plasma GZR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-dose Concentration of EBR</measure>
    <time_frame>Week 4: Predose</time_frame>
    <description>Pre-dose concentration (Ctrough) of plasma EBR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-dose Concentration of GZR</measure>
    <time_frame>Week 4: Predose</time_frame>
    <description>Pre-dose concentration (Ctrough) of plasma GZR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Number of participants experiencing adverse events (AEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuations due to an AE</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Number of participants discontinuing study drug due to AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Virologic Response</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants achieving sustained virologic response defined as HCV RNA &lt;lower limit of quantification (LLOQ) 12 weeks after the end of all study therapy (SVR12).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>EBR/GZR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ages 12 to less than 18 years will receive Fixed Dose Combination (FDC) EBR/GZR tablets once daily for 12 weeks; and ages 3 to less than 12 years will receive a pediatric formulation of EBR/GZR once daily for 12 weeks. There will be 24 weeks of follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EBR/GZR</intervention_name>
    <description>Ages 12 to less than 18 years will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily. Ages 3 to less than 12 years will receive oral granules pediatric formulation in a soft food vehicle once daily with EBR/GRZ not to exceed 50 mg/100 mg.</description>
    <arm_group_label>EBR/GZR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has documented chronic HCV genotype (GT)1 or GT4 infection

          -  Has the following liver disease staging assessment: Absence of cirrhosis; Compensated
             cirrhosis

          -  Has one of the following HCV treatment status: GT1 and GT4: HCV Treatment-naïve (TN)
             (defined as no prior exposure to any interferon [IFN]-containing regimen, ribavirin
             [RBV], or other HCV-specific direct acting antiviral (DAA) agent. GT1 only: HCV
             treatment-experienced (TE). Participants cannot have previously received treatment
             with HCV specific DAA agents.

          -  Female is not pregnant, not breastfeeding, and is either not of childbearing potential
             or follows the contraceptive guidance during the treatment period and for at least 14
             days after the last dose of study treatment.

          -  A legally acceptable representative(s) provides written informed consent for the study
             and, when applicable, the participant provides written informed assent.

        Exclusion Criteria:

          -  Has evidence of decompensated liver disease manifested by the presence of or history
             of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy, or other
             signs or symptoms of advanced liver disease.

          -  Is cirrhotic AND has a Child-Turcotte-Pugh score &gt;6, corresponding to a Child Class B
             or C.

          -  Is co-infected with Human Immunodeficiency Virus (HIV).

          -  Has evidence of past or present hepatitis B infection.

          -  Has a history of malignancy ≤5 years prior to signing informed consent or is under
             evaluation for other active or suspected malignancy.

          -  Female expects to conceive or donate eggs from Day 1 through at least 14 days after
             the last dose of study treatment or longer.

          -  Has any of the following conditions: organ transplants other than cornea and hair;
             poor venous access; history of gastric surgery or malabsorption disorders; any
             clinically significant cardiac abnormalities/dysfunction that may interfere with
             participant treatment, assessment, or compliance; any major medical condition which
             might interfere with participant treatment, assessment, or compliance; history of a
             medical/surgical condition that resulted in hospitalization within the 3 months prior
             to enrollment; medical/surgical conditions that may result in a need for
             hospitalization during the study duration; any medical condition requiring, or likely
             to require, chronic systemic administration of corticosteroids, tumor necrosis factor
             antagonists, or immunosuppressant drugs; life-threatening serious adverse event (SAE)
             during the screening period; history of chronic hepatitis not caused by HCV.

          -  Female has a positive urine pregnancy test within 24 hours before the first dose of
             study treatment.

          -  Is taking or plans to take prohibited medications, or is taking herbal supplements.

          -  Has had previous HCV direct acting antiviral (DAA) treatment.

          -  Is currently participating or has participated in a study with an investigational
             compound within prior 30 days

          -  Has significant emotional problems or a clinically significant psychiatric disorder
             that may interfere with participant treatment, assessment, or compliance with the
             protocol.

          -  Has clinically relevant drug or alcohol abuse within prior 12 months that may
             interfere with participant treatment, assessment, or compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Florida Hospital ( Site 0006)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-303-7756</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston ( Site 0009)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-355-5837</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh ( Site 0024)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>412-692-6444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>American Research Corporation ( Site 0200)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-918-8851</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Medical Center, [Seattle, WA] ( Site 0017)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-987-4636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover Kinderklinik K10 ( Site 0105)</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+495115323208</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Wuppertal GmbH ( Site 0104)</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492028963831</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>WSOZ im.T.Browicza w Bydgoszczy ( Site 0800)</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48602575396</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital im. dr W. Bieganskiego w Lodzi ( Site 0810)</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48601272443</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MED-POLONIA Sp. z o.o. ( Site 0808)</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48616561700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge. ( Site 0062)</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46858587321</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2017</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

